X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ORCHID PHARMA LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ORCHID PHARMA LTD TORRENT PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 29.0 -0.6 - View Chart
P/BV x 5.5 0.4 1,262.2% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 TORRENT PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ORCHID PHARMA LTD
Sep-13
TORRENT PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,768194 911.2%   
Low Rs1,18635 3,387.4%   
Sales per share (Unadj.) Rs346.1276.5 125.2%  
Earnings per share (Unadj.) Rs55.2-79.2 -69.7%  
Cash flow per share (Unadj.) Rs73.3-43.5 -168.7%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.153.9 476.6%  
Shares outstanding (eoy) m169.2270.45 240.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.30.4 1,030.2%   
Avg P/E ratio x26.8-1.4 -1,851.7%  
P/CF ratio (eoy) x20.1-2.6 -764.4%  
Price / Book Value ratio x5.72.1 270.6%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8878,067 3,097.8%   
No. of employees `00011.82.8 420.8%   
Total wages/salary Rs m9,9342,527 393.1%   
Avg. sales/employee Rs Th4,971.56,956.1 71.5%   
Avg. wages/employee Rs Th843.2902.5 93.4%   
Avg. net profit/employee Rs Th792.4-1,993.0 -39.8%   
INCOME DATA
Net Sales Rs m58,56919,477 300.7%  
Other income Rs m2,233407 548.4%   
Total revenues Rs m60,80219,884 305.8%   
Gross profit Rs m13,7731,103 1,249.1%  
Depreciation Rs m3,0692,519 121.8%   
Interest Rs m2,0565,227 39.3%   
Profit before tax Rs m10,881-6,236 -174.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,545-125 -1,234.1%   
Profit after tax Rs m9,336-5,580 -167.3%  
Gross profit margin %23.55.7 415.4%  
Effective tax rate %14.22.0 707.3%   
Net profit margin %15.9-28.7 -55.6%  
BALANCE SHEET DATA
Current assets Rs m53,84111,014 488.8%   
Current liabilities Rs m31,61232,060 98.6%   
Net working cap to sales %38.0-108.1 -35.1%  
Current ratio x1.70.3 495.8%  
Inventory Days Days9795 102.4%  
Debtors Days Days8434 249.6%  
Net fixed assets Rs m42,07929,440 142.9%   
Share capital Rs m846705 120.1%   
"Free" reserves Rs m42,6552,043 2,088.3%   
Net worth Rs m43,5013,800 1,144.8%   
Long term debt Rs m22,4089,018 248.5%   
Total assets Rs m101,25046,510 217.7%  
Interest coverage x6.3-0.2 -3,258.7%   
Debt to equity ratio x0.52.4 21.7%  
Sales to assets ratio x0.60.4 138.1%   
Return on assets %11.3-0.8 -1,480.3%  
Return on equity %21.5-146.9 -14.6%  
Return on capital %19.6-3.7 -525.6%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m20,0667,513 267.1%   
Fx outflow Rs m5,3045,649 93.9%   
Net fx Rs m14,7621,865 791.8%   
CASH FLOW
From Operations Rs m10,1271,682 602.2%  
From Investments Rs m-7,869-9,860 79.8%  
From Financial Activity Rs m-1,9186,644 -28.9%  
Net Cashflow Rs m212-1,535 -13.8%  

Share Holding

Indian Promoters % 71.5 32.3 221.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.6 152.6%  
FIIs % 12.6 3.3 381.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 8.8 55.3 15.9%  
Shareholders   26,511 84,811 31.3%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS